Sertraline treatment of panic disorder: results of a long-term study.
Acta Psychiatr Scand
; 104(4): 289-98, 2001 Oct.
Article
en En
| MEDLINE
| ID: mdl-11722304
ABSTRACT
OBJECTIVE:
To investigate the long-term efficacy, prevention of relapse and safety of sertraline in the treatment of panic disorder.METHOD:
This study consisted of 52 weeks of open-label sertraline treatment (n=398) followed by a 28 weeks of a double-blind, placebo-controlled discontinuation trial (n=183).RESULTS:
Ninety-three patients were randomized to sertraline and 90 were randomized to placebo. Discontinuation due to insufficient clinical response occurred in 23.6% of placebo-treated patients and 12.0% of sertraline-treated patients (log-rank test, P=0.040). Thirty-three per cent of placebo-treated patients had an exacerbation of panic symptomatology, versus 13% of sertraline-treated patients (log-rank test, P=0.005). Abrupt cessation of sertraline resulted in dizziness (4.3% sertraline vs. 16.9% placebo; P=0.007) and insomnia (4.3% sertraline vs. 15.7% placebo; P=0.013) occurring at significantly higher rates.CONCLUSION:
Long-term sertraline treatment was effective in preventing relapse of panic disorder, well tolerated and associated with minimal discontinuation symptoms.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
2_ODS3
Problema de salud:
2_sustancias_psicoativas
Asunto principal:
Trastorno de Pánico
/
Sertralina
/
Agorafobia
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Acta Psychiatr Scand
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos